Latest News and Press Releases

AAVantgarde Bio appoints Rasmus Holm-Jorgensen as CFO to support growth and advance AAV gene therapies for inherited retinal diseases.

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics...

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath

Dublin, April 14, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapies in CNS Disorders" report has been added to ResearchAndMarkets.com's offering.Currently, there are nine cell and gene...

MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Industry Trends and Global Forecasts to 2035, by...

Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and...

Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapies in Gastrointestinal Disorders: Therapeutic Analysis" report has been added to ResearchAndMarkets.com's offering.Both...

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights